

1 **Clinical Biomarker-Based Biological Aging and the Risk of**
2 **Abdominal Aortic Aneurysm: A Prospective Cohort Study**

3 **Xinyi Zhou^{1,2#}, Zaixin Yu^{1,2#}, Mukamengjiang Juaiti^{1,2}, Lihuang Zha^{1,2}, Baohua**
4 **Peng^{1,2}, Chengshuang Xiao^{1,2}, Yiyang Tang^{1,2*}**

5 ¹Department of Cardiology, Xiangya Hospital, Central South University, Changsha,
6 Hunan, China.

7 ²National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central
8 South University, Changsha, Hunan, China.

9 [#]These authors contributed equally to this work.

10 *** Correspondence:**

11 Yiyang Tang, MD

12 Email: tangyiyang@csu.edu.cn

13 Address: No.87 Xiangya Road, Kaifu District, Changsha, Hunan, China.

14 **Abstract**

15 **Background:** Compared to chronological age, biological age (BA), a concept
16 introduced in recent years, more accurately reflects the true aging status of the body.

17 While biological aging has been found to be associated with various cardiovascular
18 diseases, its relationship with abdominal aortic aneurysm (AAA) remains unclear.

19 **Methods:** This study utilized data extracted from UK Biobank for analysis. Telomere
20 length (TL), and BA acceleration calculated using the Klemmera-Doubal (KDM) and
21 PhenoAge methods, were employed as surrogate measures to assess biological aging.
22 Cox regression was primarily performed to explore the association between biological
23 aging and AAA risk. Genetic susceptibility was assessed by constructing a polygenic
24 risk score (PRS).

25 **Results:** This study included 311,646 participants, predominantly women and White,
26 with a median age of 58 years. During a median follow-up of 12.54 years, 1,339 new
27 cases of AAA (4.3‰) were reported. Each standard deviation (SD) decrease in TL
28 was associated with a 20% increased risk of AAA (HR=1.20, 95% CI=1.14-1.27);
29 each SD increase in KDM-BA acceleration was associated with a 21% increased risk
30 (HR=1.21, 95% CI=1.12-1.29); and each SD increase in PhenoAge acceleration was
31 associated with a 40% increased risk (HR=1.40, 95% CI=1.32-1.48). These
32 associations were independent of genetic risk, as assessed by the PRS, and
33 demonstrated a joint effect with genetic predisposition on the long-term risk of AAA.

34 **Conclusion:** Accelerated biological aging was longitudinally associated with an
35 increased risk of AAA, suggesting it may be a significant factor and potential
36 biomarker for the occurrence of the condition.

37 **Keywords:** Biological aging, Abdominal aortic aneurysm, UK Biobank, Genetic
38 susceptibility.

39 **Background**

40 Abdominal aortic aneurysm (AAA) is the most common form of aortic aneurysm,
41 characterized by the permanent and localized dilation of the abdominal aorta[1]. It is
42 often asymptomatic until rupture, a catastrophic event with a mortality rate of up to
43 80%, highlighting its significant public health burden[2]. Therefore, identifying and
44 validating biomarkers associated with AAA occurrence is of significant public health
45 importance, as it can enhance early diagnosis, improve management strategies, and
46 ultimately optimize patient outcomes.

47 AAA is a degenerative disease associated with aging[3]. Traditionally, chronological
48 age has been used to assess an individual's level of aging and disease risk[4].
49 However, chronological age has limitations, as individuals of the same or similar
50 chronological age can exhibit significant differences in functional status and aging
51 processes due to factors such as genetics, environment, and lifestyle[5]. Recently,
52 biological age has been proposed as a more comprehensive and accurate measure of
53 aging, incorporating indicators such as telomere length (TL), Klemera-Doubal method
54 biological age (KDM-BA), and phenotypic age (PhenoAge)[6]. Previous studies have
55 shown that increased biological age is significantly associated with higher mortality
56 and elevated risks of various cardiovascular diseases, including heart failure[7, 8].
57 However, the relationship between biological aging and the incidence of AAA
58 remains unclear. Additionally, AAA has a genetic predisposition, with genome-wide
59 association studies (GWAS) identifying several single-nucleotide polymorphisms

60 (SNPs) linked to AAA risk[9, 10]. The interaction between genetic susceptibility and
61 biological aging in relation to AAA risk has not yet been fully explored.

62 To fill this research gap, this study uses a prospective cohort from the UK Biobank to
63 examine the longitudinal associations between biological aging and AAA risk, and to
64 investigate the joint effects and interactions between genetic susceptibility and
65 biological aging on the long-term risk of AAA.

66 **Methods**

67 **Study population**

68 The data used in this study were obtained from the UK Biobank (ID: 107175). The
69 UK Biobank is a large-scale prospective cohort study that recruited over 500,000
70 volunteers across the United Kingdom between 2006 and 2010[11]. This study
71 received ethical approval from the North West Multi-Centre Research Ethics
72 Committee (Ref: 11/NW/0382), and all participants provided informed consent by
73 signing a consent form.

74 Of the 502,163 participants in the UK Biobank, we excluded 460 participants with
75 baseline AAA, 177,504 participants missing biomarkers required for the KDM-BA
76 and PhenoAge algorithms, 11,531 participants missing TL measurements, and 1,022
77 participants with missing covariate data. A total of 311,646 participants were included
78 in the final analysis. The participant selection process was shown in **Figure S1**.

79 **Study Outcomes**

80 The outcome variable of this study was the occurrence of AAA, which was
81 determined based on hospital admission and death registration records (**Table S1**).

82 The diagnosis of AAA was identified using the Tenth Revision of the International
83 Classification of Diseases (ICD-10 codes: I71.3, I71.4) and the Office of Population,
84 Censuses and Surveys: Classification of Interventions and Procedures (OPCS-4 codes:
85 L18*, L19*, L254, L27*, L28*, L464), as used in prior studies[12]. The study period
86 began when participants entered the cohort and ended upon the diagnosis of AAA,
87 loss to follow-up, death, or completion of follow-up, whichever occurred first. The
88 follow-up cut-off date was September 30, 2021, for England and Wales, and October
89 31, 2021, for Scotland.

90 **Measurement of TL**

91 TL was measured using a multiplex quantitative polymerase chain reaction method,
92 with samples obtained from peripheral blood leukocytes. Specifically, TL was
93 quantified relative to the ratio of telomere repeat copy number to single-copy gene
94 (T/S), and the data were log-transformed and Z-standardized. Detailed information on
95 the measurement and adjustment of TL can be found in previous studies[13].

96 **Calculation of KDM-BA and PhenoAge**

97 The KDM-BA and PhenoAge algorithms[8, 14, 15] are widely recognized biological
98 age measures based on clinical parameters (**Table S2**). These algorithms were
99 developed using optimal training models derived from the National Health and
100 Nutrition Examination Survey (NHANES) and have been further validated with data
101 from the UK Biobank. Using the R package “BioAge”
102 (<https://github.com/dayoonkwon/BioAge>), KDM-BA was calculated based on forced
103 expiratory volume in one second, systolic blood pressure, and seven blood chemistry

104 parameters: albumin, alkaline phosphatase, blood urea nitrogen, creatinine, C-reactive
105 protein (CRP), glycated hemoglobin, and total cholesterol. PhenoAge was calculated
106 using nine hematological indicators: albumin, alkaline phosphatase, creatinine, CRP,
107 glucose, mean corpuscular volume, red cell distribution width, white blood cell count,
108 and lymphocyte percentage. We then regressed the calculated biological age values
109 against the chronological age at the time of biomarker measurement and computed the
110 residuals[16]. These residuals were termed “age acceleration” (AA) values, which
111 were used to assess biological aging. The AA values were then standardized with a
112 mean of 0 and a standard deviation of 1 for comparison in subsequent analyses. More
113 details can be found in **Method S1**.

114 **Covariates**

115 The covariates considered in this study mainly included age, sex, ethnicity, education
116 level, Townsend Deprivation Index (TDI), CRP, body mass index (BMI), smoking
117 and alcohol consumption status, physical activity, sleep and dietary patterns, as well
118 as medical history of hyperlipidemia, hypertension, and diabetes. Detailed definitions
119 and descriptions of these covariates can be found in **Method S2**.

120 **Statistical analysis**

121 The continuous variables were found not to follow a normal distribution based on the
122 quantile-quantile plot and were therefore expressed as medians [interquartile range
123 (IQR)]. Group comparisons were performed using the Mann-Whitney U test or
124 Kruskal-Wallis H test. Categorical variables were represented as frequencies
125 (percentages), and group comparisons were conducted using chi-square tests.

126 TL, KDM-BA, and PhenoAge acceleration were treated as continuous variables or
127 categorized based on quartiles, and their associations with AAA occurrence were
128 assessed using Cox proportional hazards models, with results presented as hazard
129 ratios (HR) and 95% confidence intervals (95% CI). The Schoenfeld residual test
130 confirmed no violations of the proportional hazards assumption. Model 1 adjusted for
131 age, sex, ethnicity, education level, and TDI. Model 2 further adjusted for smoking
132 and drinking status, physical activity, sleep and dietary patterns, BMI, CRP, and
133 medical history of hypertension, hyperlipidemia, and diabetes. Additionally, based on
134 Cox regression Model 2, a restricted cubic spline (RCS) with three knots was used to
135 analyze the dose-response relationship between biological aging and AAA risk.

136 We included only participants of White ancestry and constructed a polygenic risk
137 score (PRS) to assess individuals' genetic susceptibility to AAA[17] (**Method S3**).

138 We then evaluated the joint effect of genetic susceptibility and biological aging on the
139 risk of AAA. Participants were categorized into 12 groups based on their levels of
140 biological aging and genetic susceptibility. Using the group with the lowest levels of
141 both biological aging and genetic susceptibility as a reference, we estimated the HR
142 and 95% CI for AAA occurrence in the other groups, after adjusting for covariates in
143 Model 2. Stratified analyses were conducted to assess the separate effect of biological
144 aging on AAA incidence at different levels of genetic susceptibility, and the
145 likelihood ratio test was used to evaluate the interaction between biological aging and
146 genetic susceptibility.

147 Subgroup analyses were also conducted to assess potential modifying effects on the
148 association between biological aging and the risk of AAA. Sensitivity analyses
149 included: 1. Excluding participants who developed AAA within the first year of
150 follow-up; 2. Using the Fine-Gray model to account for mortality as a competing risk.
151 All analyses were performed in R (version 4.3.2), with p -values < 0.05 considered
152 statistically significant.

153 **Results**

154 **Baseline of the participants**

155 This study included a total of 311,646 participants (**Figure S1**), of whom 168,249
156 (54.0%) were women. The majority of participants were White, comprising 294,574
157 individuals or 94.5% of the total cohort (**Table S3**). The median age was 58 years
158 (IQR: 50–63 years), with median values of KDM-BA and PhenoAge recorded at
159 49.82 years (IQR: 40.90-58.26) and 45.83 years (IQR: 38.10-52.54), respectively.
160 KDM-BA ($r = 0.67$) and PhenoAge ($r = 0.86$) were strongly positively correlated with
161 chronological age, whereas TL showed a weak negative correlation ($r = -0.20$, **Figure**
162 **S2**).

163 Baseline characteristics, stratified by quartiles of TL, PhenoAge acceleration, and
164 KDM-BA acceleration, were summarized in **Table 1** and **Tables S4–S5**. Participants
165 with shorter TL were more likely to be men, have lower educational attainment, and
166 engage in unhealthy lifestyle behaviors (e.g., current smoking, poor sleep patterns,
167 and insufficient physical activity). They also exhibited higher prevalence rates of
168 diabetes, hyperlipidemia, and hypertension. Similar trends were observed for baseline

169 characteristics stratified by quartiles of KDM-BA acceleration and PhenoAge
170 acceleration.

171 **Association between biological aging and the risk of AAA**

172 During a median follow-up of 12.54 years (IQR: 11.87-13.16), a total of 1,339 (4.3%)
173 incident cases of AAA were reported. Overall, accelerated biological aging was
174 significantly positively associated with an increased long-term risk of AAA (**Table 2**).
175 Specifically, for each standard deviation decrease in TL, the risk of AAA increased by
176 20% (HR = 1.20, 95% CI = 1.14-1.27); for each standard deviation increase in
177 KDM-BA acceleration, the risk increased by 21% (HR = 1.21, 95% CI = 1.12-1.29);
178 and for each standard deviation increase in PhenoAge acceleration, the risk increased
179 by 40% (HR = 1.40, 95% CI = 1.32-1.48). Consistently, compared with participants
180 with longer TL, lower KDM-BA acceleration, or lower PhenoAge acceleration, those
181 with shorter TL, higher KDM-BA acceleration, or higher PhenoAge acceleration had
182 significantly higher risks of AAA. Furthermore, **Figure 1** demonstrated the potential
183 dose-response relationships between biological aging and AAA risk. The results
184 indicated a linear association between TL, KDM-BA acceleration, PhenoAge
185 acceleration, and AAA occurrence (p -value for non-linearity > 0.05).

186 **Joint and interaction analysis of biological aging and genetic predisposition**

187 The results in **Table S6** indicated that the constructed PRS score effectively predicted
188 the risk of AAA occurrence. After further adjusting for PRS in Models 1 and 2, the
189 significant association between biological aging indicators and AAA risk persisted
190 (**Table S7**).

191 The joint effects of biological aging and genetic susceptibility on the risk of AAA
192 were shown in **Figure 2A-C**. Overall, the risk of AAA increased with accelerated
193 biological aging and higher levels of genetic susceptibility (p -value for trend < 0.001).
194 Compared to participants with the lowest PRS and biological aging, those with the
195 highest PRS and biological aging exhibited the highest risk of AAA (high PRS and Q1
196 of TL: HR = 1.81, 95% CI = 1.31-2.49; high PRS and Q4 of KDM-BA acceleration:
197 HR = 2.43, 95% CI = 1.79-3.28; high PRS and Q4 of PhenoAge acceleration: HR =
198 3.27, 95% CI = 2.21-4.85). Additionally, at different levels of genetic susceptibility,
199 higher levels of biological aging were positively associated with the occurrence of
200 AAA (**Figure 2D-F**). No significant interaction was observed between genetic
201 susceptibility and biological aging indicators regarding the risk of AAA (p -value for
202 interaction > 0.05).

203 **Subgroup and sensitivity analyses**

204 As shown in **Table 3**, subgroup analyses indicated that the association between
205 shortened TL and the incidence of AAA was significant only in men, rather than in
206 women (p -value for the interaction between sex and TL = 0.018). For other
207 stratification factors, no significant differences were observed in the associations
208 between biological aging indicators and AAA occurrence (p -value for the interaction >
209 0.05, **Table S8-9**). Sensitivity analyses, including the exclusion of participants who
210 reported AAA in the first year (**Table S10**) and the application of Fine-Gray
211 competing risk regression models (**Figure S3**), consistently supported the strong
212 association between high levels of biological aging and an increased incidence of

213 AAA.

214 **Discussion**

215 In this study, we utilized the large-scale prospective cohort of the UK Biobank to
216 investigate the association between clinical biomarker-based biological aging and the
217 long-term risk of AAA. The main findings are as follows: accelerated biological aging
218 (reflected by shortened TL, higher KDM-BA, and PhenoAge acceleration) was
219 significantly associated with an increased risk of AAA. This association was
220 independent of genetic risk assessed by PRS and demonstrated a joint effect with
221 genetic predisposition. Furthermore, sex appeared to modify the relationship between
222 TL and AAA risk, with the association between shortened TL and an increased risk of
223 AAA being significant only in men.

224 The association between biological aging and cardiovascular diseases has gradually
225 been recognized[18, 19], and accurately measuring biological age is key to further
226 studying this relationship[20]. To this end, various indicators for assessing an
227 individual's biological age have been proposed, each of which is distinctive in
228 reflecting different dimensions and mechanisms of the aging process. Telomeres are
229 tandemly repeated nucleotide sequences located at the ends of chromosomes, and TL
230 is considered a key indicator of biological aging[21]. When telomeres shorten to a
231 critical threshold, an irreparable DNA damage response is triggered, leading to the
232 cessation of cell division and, consequently, aging[22]. A study by Atturu et al.[23]
233 showed that, compared to the control group, patients with AAA had shorter leukocyte
234 telomeres, and this telomere shortening was significantly associated with AAA (odds

235 ratio [OR] = 2.30, 95% CI =1.28-4.13). However, this was a case-control study with a
236 limited sample size (N = 373), and it did not establish a longitudinal association
237 between TL and the occurrence of AAA. This study partially addressed this issue and
238 provided stronger evidence. We also found an interesting interaction between TL and
239 sex. The association between biological aging and AAA risk was only significant in
240 men. The remodeling of the extracellular matrix has been found to be more
241 pronounced in the aging process of men compared to women, as evidenced by
242 increased aortic diameter and stiffness[24]. This may be attributed to the protective
243 effects of estrogen[25]. In addition, several composite biomarker algorithms, such as
244 KDM-BA and PhenoAge, have been proposed in recent years to estimate an
245 individual's biological age. Compared to single indicators like TL, these algorithms
246 are more reliable and comprehensive, as they integrate a range of clinical biomarkers
247 and anthropometric data while also considering multiple dimensions, such as
248 metabolism, immunity, inflammation, and organ homeostasis[26]. Furthermore, their
249 high accessibility and affordability further enhance their potential for widespread
250 application.

251 Biological aging may contribute to the development of AAA through various
252 mechanisms. Chronic low-grade inflammation is a significant characteristic of aging
253 and a key mechanism in AAA development. Senescent cells secrete a complex array
254 of factors, including pro-inflammatory cytokines, chemokines, growth factors, and
255 matrix metalloproteinases[27]. These factors can recruit various inflammatory cells to
256 infiltrate the vascular wall, creating an inflammatory microenvironment that

257 compromises aortic structural integrity and promotes the occurrence of AAA[28].
258 Additionally, oxidative stress may partly explain the association between biological
259 aging and AAA. Research has shown that aging is related to the dysfunction of
260 nuclear factor E2-related factor 2 in the aorta, exacerbating oxidative stress and
261 increasing sensitivity to reactive oxygen species-mediated damage[29]. Moreover, the
262 phenotypic transformation of smooth muscle cells is another important mechanism in
263 the development of aortic aneurysms. Under pressure induction, aging vascular
264 smooth muscle cells secrete fibroblast growth factor 9, causing adjacent normal
265 vascular smooth muscle cells to undergo phenotypic transformation, which may
266 contribute to the formation of AAA[30].

267 The strength of this study lies in establishing, for the first time, a longitudinal
268 association between biological aging and the long-term risk of AAA. The large
269 sample size and high-quality data from the UK Biobank prospective cohort ensured
270 the credibility of the study results. Additionally, this study is notably comprehensive,
271 utilizing three different indicators to assess individual biological aging levels: TL, a
272 key marker of aging, and KDM-BA and PhenoAge, which are calculated based on
273 multidimensional biomarkers. Furthermore, we also took into account the role of
274 genetic susceptibility in this association. This study also has some limitations. First, as
275 an observational study, it cannot establish causality or clarify the specific mechanisms
276 underlying the association between biological aging and AAA. Second, biological
277 aging was assessed solely through baseline data, preventing further exploration of the
278 relationship between longitudinal changes in biological aging and AAA risk.

279 Although multiple confounding factors were adjusted for, the study cannot rule out
280 the potential influence of important confounders not available in the UK Biobank.
281 Additionally, since the participants of the UK Biobank were primarily White, the
282 generalizability of the findings to other populations needs further confirmation.

283 **Conclusion**

284 Biomarker-based biological aging is significantly associated with the long-term risk
285 of AAA, independent of genetic susceptibility. These findings highlight the potential
286 utility of biological aging assessments in identifying high-risk populations for AAA,
287 providing valuable insights for its prevention and management.

288 **Declarations**

289 **Ethics approval and consent to participate**

290 This study was approved by the North West Multi-Centre Research Ethics Committee
291 (Reference: 11/NW/0382). All participants provided written informed consent prior to
292 participation.

293 **Consent for publication**

294 Not applicable.

295 **Availability of data and materials**

296 The data supporting the findings of this study were obtained from the UK Biobank
297 Resource under Application No. 107175. These data can be accessed by submitting an
298 application through the UK Biobank official website (www.ukbiobank.ac.uk).

299 **Competing interests**

300 The authors declare no competing interests.

301 **Funding**

302 This work was supported by the National Natural Science Foundation of China (Grant
303 Nos. 82470054 and 82300081), the Hunan Provincial Natural Science Foundation of
304 China (Grant Nos. 2023JJ40963, 2024JJ6620, and 2024JJ6673), and the Project
305 Program of the National Clinical Research Center for Geriatric Disorders (Xiangya
306 Hospital, Grant No. 2023LNJJ18).

307 **Author contributions**

308 This study was conceived and designed by Yiyang Tang. Xinyi Zhou and Zaixin Yu
309 performed the data analysis and drafted the manuscript. Mukamengjiang Juaiti and

310 Lihuang Zha contributed to the statistical analysis. Baohua Peng assisted with data
311 interpretation and visualization. Chengshuang Xiao revised the manuscript and
312 provided constructive feedback. All authors reviewed and approved the final
313 manuscript.

314 **Acknowledgements**

315 The authors sincerely thank the management team and participants of the UK Biobank
316 for their invaluable contributions to this study.

317 **Reference:**

318 [1] Zhou M, Wang X, Shi Y, Ding Y, Li X, Xie T, *et al.* (2021). Deficiency of ITGAM
319 Attenuates Experimental Abdominal Aortic Aneurysm in Mice. *J Am Heart Assoc*,
320 10:e019900.

321 [2] Wanhainen A, Verzini F, Van Herzele I, Allaire E, Bown M, Cohnert T, *et al.* (2019).
322 Editor's Choice - European Society for Vascular Surgery (ESVS) 2019 Clinical
323 Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms.
324 *Eur J Vasc Endovasc Surg*, 57:8-93.

325 [3] Wang D, Hao X, Jia L, Jing Y, Jiang B, Xin S (2022). Cellular senescence and
326 abdominal aortic aneurysm: From pathogenesis to therapeutics. *Front Cardiovasc*
327 *Med*, 9:999465.

328 [4] Fan H, Xie Q, Zhang Z, Wang J, Chen X, Qiu P (2021). Chronological Age Prediction:
329 Developmental Evaluation of DNA Methylation-Based Machine Learning Models.
330 *Front Bioeng Biotechnol*, 9:819991.

331 [5] Salih A, Nichols T, Szabo L, Petersen SE, Raisi-Estabragh Z (2023). Conceptual

- 332 Overview of Biological Age Estimation. *Aging Dis*, 14:583-588.
- 333 [6] Zhang C, Ling Z, Xiang L, Zhang Y, Li L, Yang S, *et al.* (2024). Association of
334 accelerated aging with the incidence risk of Cardiometabolic diseases in people with
335 severe mental illnesses: A prospective analysis in UK Biobank. *Psychiatry Res*,
336 337:115930.
- 337 [7] Mao R, Wang F, Zhong Y, Meng X, Zhang T, Li J (2024). Association of Biological Age
338 Acceleration with Cardiac Morphology, Function, and Incident Heart Failure: Insights
339 from UK Biobank Participants. *Eur Heart J Cardiovasc Imaging*.
- 340 [8] Liu Z, Kuo PL, Horvath S, Crimmins E, Ferrucci L, Levine M (2018). A new aging
341 measure captures morbidity and mortality risk across diverse subpopulations from
342 NHANES IV: A cohort study. *PLoS Med*, 15:e1002718.
- 343 [9] Roychowdhury T, Klarin D, Levin MG, Spin JM, Rhee YH, Deng A, *et al.* (2023).
344 Genome-wide association meta-analysis identifies risk loci for abdominal aortic
345 aneurysm and highlights PCSK9 as a therapeutic target. *Nat Genet*, 55:1831-1842.
- 346 [10] Zheng S, Tsao PS, Pan C (2024). Abdominal aortic aneurysm and cardiometabolic
347 traits share strong genetic susceptibility to lipid metabolism and inflammation. *Nat*
348 *Commun*, 15:5652.
- 349 [11] Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, *et al.* (2015). UK biobank:
350 an open access resource for identifying the causes of a wide range of complex
351 diseases of middle and old age. *PLoS Med*, 12:e1001779.
- 352 [12] Ma Y, Li D, Cui F, Wang J, Tang L, Yang Y, *et al.* (2024). Air pollutants, genetic
353 susceptibility, and abdominal aortic aneurysm risk: a prospective study. *Eur Heart J*,

354 45:1030-1039.

355 [13] Codd V, Denniff M, Swinfield C, Warner SC, Papakonstantinou M, Sheth S, *et al.*
356 (2021). A major population resource of 474,074 participants in UK Biobank to
357 investigate determinants and biomedical consequences of leukocyte telomere
358 length.2021.2003.2018.21253457.

359 [14] Levine ME (2013). Modeling the rate of senescence: can estimated biological age
360 predict mortality more accurately than chronological age? J Gerontol A Biol Sci Med
361 Sci, 68:667-674.

362 [15] Klemmera P, Doubal S (2006). A new approach to the concept and computation of
363 biological age. Mech Ageing Dev, 127:240-248.

364 [16] Gao X, Geng T, Jiang M, Huang N, Zheng Y, Belsky DW, *et al.* (2023). Accelerated
365 biological aging and risk of depression and anxiety: evidence from 424,299 UK
366 Biobank participants. Nat Commun, 14:2277.

367 [17] Kurki MI, Karjalainen J, Palta P, Sipila TP, Kristiansson K, Donner KM, *et al.* (2023).
368 FinnGen provides genetic insights from a well-phenotyped isolated population. Nature,
369 613:508-518.

370 [18] Moturi S, Ghosh-Choudhary SK, Finkel T (2022). Cardiovascular disease and the
371 biology of aging. J Mol Cell Cardiol, 167:109-117.

372 [19] North BJ, Sinclair DA (2012). The intersection between aging and cardiovascular
373 disease. Circ Res, 110:1097-1108.

374 [20] Zhang X, Zhao H, Li Z, Liu X, Zhang Y, Yang N, *et al.* (2024). Accelerated biological
375 aging, healthy behaviors, and genetic susceptibility with incidence of stroke and its

- 376 subtypes: A prospective cohort study. *Aging Cell*:e14427.
- 377 [21] Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, *et al.* (1999).
378 Mammalian telomeres end in a large duplex loop. *Cell*, 97:503-514.
- 379 [22] Leao R, Apolonio JD, Lee D, Figueiredo A, Tabori U, Castelo-Branco P (2018).
380 Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical
381 impacts in cancer. *J Biomed Sci*, 25:22.
- 382 [23] Atturu G, Brouillette S, Samani NJ, London NJ, Sayers RD, Bown MJ (2010). Short
383 leukocyte telomere length is associated with abdominal aortic aneurysm (AAA). *Eur J*
384 *Vasc Endovasc Surg*, 39:559-564.
- 385 [24] Villard C, Hultgren R (2018). Abdominal aortic aneurysm: Sex differences. *Maturitas*,
386 109:63-69.
- 387 [25] Makrygiannis G, Courtois A, Drion P, Defraigne JO, Kuivaniemi H, Sakalihasan N
388 (2014). Sex differences in abdominal aortic aneurysm: the role of sex hormones. *Ann*
389 *Vasc Surg*, 28:1946-1958.
- 390 [26] Chen L, Wu B, Mo L, Chen H, Zhao Y, Tan T, *et al.* (2024). Associations between
391 biological ageing and the risk of, genetic susceptibility to, and life expectancy
392 associated with rheumatoid arthritis: a secondary analysis of two observational studies.
393 *Lancet Healthy Longev*, 5:e45-e55.
- 394 [27] Yang L, Wu X, Bian S, Zhao D, Fang S, Yuan H (2024). SIRT6-mediated vascular
395 smooth muscle cells senescence participates in the pathogenesis of abdominal aortic
396 aneurysm. *Atherosclerosis*, 392:117483.
- 397 [28] Raucci A, Macri F, Castiglione S, Badi I, Vinci MC, Zuccolo E (2021). MicroRNA-34a:

- 398 the bad guy in age-related vascular diseases. *Cell Mol Life Sci*, 78:7355-7378.
- 399 [29] Ungvari Z, Bailey-Downs L, Sosnowska D, Gautam T, Koncz P, Losonczy G, *et al.*
400 (2011). Vascular oxidative stress in aging: a homeostatic failure due to dysregulation
401 of NRF2-mediated antioxidant response. *Am J Physiol Heart Circ Physiol*,
402 301:H363-372.
- 403 [30] Xie J, Tang Z, Chen Q, Jia X, Li C, Jin M, *et al.* (2023). Clearance of Stress-Induced
404 Premature Senescent Cells Alleviates the Formation of Abdominal Aortic Aneurysms.
405 *Aging Dis*, 14:1778-1798.
406

407 **Figure legends:**

408 **Figure 1.** Association between biological aging and the risk of AAA using restricted
409 cubic splines model with three knots.

410 Abbreviation: AAA, abdominal aortic aneurysm; KDM-BA, Klemmera-Doubal method
411 biological age; PhenoAge, phenotypic age; HR, hazard ratio; CI, confidence interval.

412 **Figure 2.** Separate and joint association of biological aging with the risk of AAA in
413 individuals with different levels of genetic susceptibility.

414 The result was presented as HR (95% CI) using the Cox proportional hazards model
415 adjusted for age, sex, ethnicity, Townsend deprivation index, education levels, body
416 mass index, C-reactive protein, smoking and drinking status, physical activity, sleep
417 and diet patterns, history of hyperlipemia, hypertension, and diabetes mellitus

418 Abbreviation: AAA, abdominal aortic aneurysm; KDM-BA, Klemmera-Doubal method
419 biological age; PhenoAge, phenotypic age; HR, hazard ratio; CI, confidence interval.

420 **Table 1.** Baseline characteristics of study participants grouped by telomere length quartiles.

Variables	Total	Telomere length				<i>p</i> value
		Q4	Q3	Q2	Q1	
N	311646	77912	77911	77911	77912	
Age (years)	58.00 [50.00, 63.00]	55.00 [47.00, 61.00]	57.00 [49.00, 62.00]	58.00 [51.00, 63.00]	60.00 [53.00, 65.00]	<0.001
Women, n (%)	168249 (54.0)	46842 (60.1)	43183 (55.4)	40641 (52.2)	37583 (48.2)	<0.001
White, n (%)	294574 (94.5)	72266 (92.8)	73538 (94.4)	74127 (95.1)	74643 (95.8)	<0.001
TDI	-2.20 [-3.67, 0.39]	-2.13 [-3.63, 0.51]	-2.19 [-3.67, 0.39]	-2.22 [-3.68, 0.33]	-2.24 [-3.68, 0.34]	<0.001
Education, n (%)						<0.001
College	101091 (32.4)	28303 (36.3)	25913 (33.3)	24385 (31.3)	22490 (28.9)	
High school	35071 (11.3)	9517 (12.2)	8918 (11.4)	8696 (11.2)	7940 (10.2)	
Middle school	67420 (21.6)	16538 (21.2)	16993 (21.8)	16990 (21.8)	16899 (21.7)	
Others	108064 (34.7)	23554 (30.2)	26087 (33.5)	27840 (35.7)	30583 (39.3)	
BMI, Kg/m²	26.68 [24.11, 29.79]	26.33 [23.81, 29.44]	26.64 [24.06, 29.76]	26.78 [24.20, 29.86]	26.98 [24.39, 30.07]	<0.001
CRP, mg/L	1.30 [0.64, 2.67]	1.19 [0.59, 2.50]	1.27 [0.63, 2.61]	1.32 [0.66, 2.70]	1.41 [0.71, 2.85]	<0.001
Drinking status, n (%)						<0.001
Never	13303 (4.3)	3577 (4.6)	3402 (4.4)	3179 (4.1)	3145 (4.0)	
Previous	10545 (3.4)	2586 (3.3)	2595 (3.3)	2578 (3.3)	2786 (3.6)	
Current	287103 (92.1)	71568 (91.9)	71750 (92.1)	71978 (92.4)	71807 (92.2)	

Smoking status, n (%)						<0.001
Never	171217 (54.9)	45181 (58.0)	43698 (56.1)	42177 (54.1)	40161 (51.5)	
Previous	107241 (34.4)	24874 (31.9)	26162 (33.6)	27418 (35.2)	28787 (36.9)	
Current	31733 (10.2)	7496 (9.6)	7714 (9.9)	7948 (10.2)	8575 (11.0)	
Physical activity, n						<0.001
Regular	122958 (39.5)	31809 (40.8)	31060 (39.9)	30289 (38.9)	29800 (38.2)	
Excessive	75514 (24.2)	18426 (23.6)	18780 (24.1)	19133 (24.6)	19175 (24.6)	
Poor	43693 (14.0)	11063 (14.2)	10928 (14.0)	10956 (14.1)	10746 (13.8)	
Sleep pattern, n (%)						<0.001
Healthy	151320 (48.6)	38635 (49.6)	38006 (48.8)	37521 (48.2)	37158 (47.7)	
Intermediate	100598 (32.3)	24512 (31.5)	25132 (32.3)	25319 (32.5)	25635 (32.9)	
Poor	5807 (1.9)	1337 (1.7)	1439 (1.8)	1475 (1.9)	1556 (2.0)	
Diet pattern, n (%)						<0.001
Healthy	117408 (37.7)	30256 (38.8)	29456 (37.8)	29244 (37.5)	28452 (36.5)	
Intermediate	145882 (46.8)	35983 (46.2)	36512 (46.9)	36562 (46.9)	36825 (47.3)	
Poor	35506 (11.4)	8586 (11.0)	8806 (11.3)	8857 (11.4)	9257 (11.9)	
Medical history, n (%)						
Hyperlipidemia	144832 (46.5)	33301 (42.7)	35561 (45.6)	37139 (47.7)	38831 (49.8)	<0.001
Hypertension	170827 (54.8)	38908 (49.9)	41630 (53.4)	43982 (56.5)	46307 (59.4)	<0.001
Diabetes mellitus	17765 (5.7)	3562 (4.6)	4152 (5.3)	4597 (5.9)	5454 (7.0)	<0.001

421 Abbreviation: TDI, Townsend deprivation index; CRP, C-reactive protein; BMI, body mass index.

422

Table 2. Association between biological aging and the risk of abdominal aortic aneurysm.

Variables	Cases/N	Incidence rate*	Model 1		Model 2	
			HR (95%CI)	<i>p</i> value	HR (95%CI)	<i>p</i> value
Telomere length						
Q4	164/77912	1.703	1 (reference)		1 (reference)	
Q3	270/77911	2.813	1.26 (1.04, 1.53)	0.021	1.23 (1.02, 1.50)	0.034
Q2	360/77911	3.765	1.38 (1.15, 1.66)	0.001	1.33 (1.11, 1.60)	0.002
Q1	545/77912	5.755	1.67 (1.40, 1.99)	<0.001	1.56 (1.31, 1.86)	<0.001
Continuous	1339/311646	3.499	1.23 (1.16, 1.29)	<0.001	1.20 (1.14, 1.27)	<0.001
KDM-BA acceleration						
Q1	420/77912	4.386	1 (reference)		1 (reference)	
Q2	455/77911	4.764	1.61 (1.41, 1.84)	<0.001	1.23 (1.08, 1.42)	0.003
Q3	165/77911	1.715	1.93 (1.59, 2.34)	<0.001	1.25 (1.02, 1.53)	0.034
Q4	299/77912	3.143	3.18 (2.70, 3.75)	<0.001	1.67 (1.37, 2.02)	<0.001
Continuous	1339/311646	3.499	1.53 (1.44, 1.62)	<0.001	1.21 (1.12, 1.29)	<0.001
PhenoAge acceleration						
Q1	131/77912	1.349	1 (reference)		1 (reference)	
Q2	212/77911	2.197	1.28 (1.03, 1.59)	0.027	1.15 (0.93, 1.44)	0.202
Q3	335/77911	3.497	1.81 (1.48, 2.22)	<0.001	1.48 (1.20, 1.82)	<0.001
Q4	661/77912	7.09	3.36 (2.78, 4.06)	<0.001	2.15 (1.76, 2.63)	<0.001
Continuous	1339/311646	3.499	1.61 (1.54, 1.70)	<0.001	1.40 (1.32, 1.48)	<0.001

424 *The incidence rate was reported as per 10,000 person-years.

425 Model 1 adjusted for age, sex, ethnicity, Townsend deprivation index, education levels.

426 Model 2 adjusted for model 1 plus body mass index, C-reactive protein, smoking and drinking status, physical activity, sleep and diet patterns,
427 history of hyperlipemia, hypertension, and diabetes mellitus.

428 Abbreviation: KDM-BA, Klemera-Doubal method biological age; PhenoAge, phenotypic age; HR, hazard ratio; CI, confidence interval.

Table 3. Subgroup analysis for the association between telomere length with the risk of abdominal aortic aneurysm.

Subgroup	Cases/N	Telomere length				<i>p</i> for interaction
		Q4	Q3	Q2	Q1	
Age						0.409
<65	665/253654	1 (reference)	1.31 (1.01, 1.71)	1.63 (1.27, 2.10)	1.94 (1.52, 2.46)	
≥65	674/57992	1 (reference)	1.06 (0.83, 1.36)	1.26 (1.00, 1.60)	1.63 (1.30, 2.03)	
Sex						0.018
Women	205/168249	1 (reference)	0.84 (0.55, 1.29)	0.79 (0.52, 1.19)	1.00 (0.68, 1.47)	
Men	1134/143397	1 (reference)	1.32 (1.07, 1.62)	1.45 (1.19, 1.76)	1.69 (1.40, 2.04)	
Ethnicity						0.829
White	1308/294574	1 (reference)	1.26 (1.04, 1.53)	1.32 (1.10, 1.60)	1.56 (1.31, 1.86)	
Non-White	31/17072	1 (reference)	1.21 (0.29, 5.09)	1.35 (0.35, 5.16)	1.99 (0.56, 7.03)	
TDI						0.557
Low	411/104004	1 (reference)	1.55 (1.08, 2.24)	1.64 (1.15, 2.33)	1.84 (1.31, 2.58)	
Moderate	445/103925	1 (reference)	1.05 (0.77, 1.44)	1.02 (0.75, 1.38)	1.29 (0.97, 1.71)	
High	483/103717	1 (reference)	1.19 (0.85, 1.66)	1.47 (1.07, 2.02)	1.65 (1.22, 2.24)	
Education						0.519
College	223/101091	1 (reference)	1.62 (1.01, 2.61)	1.43 (0.89, 2.29)	1.83 (1.17, 2.86)	
High school	109/35071	1 (reference)	2.06 (0.99, 4.31)	1.99 (0.97, 4.09)	2.39 (1.19, 4.76)	
Middle school	289/67420	1 (reference)	1.12 (0.75, 1.69)	1.28 (0.87, 1.88)	1.26 (0.87, 1.83)	
Others	718/108064	1 (reference)	1.15 (0.89, 1.49)	1.22 (0.96, 1.57)	1.61 (1.27, 2.02)	

Hypertension						0.647
No	235/140819	1 (reference)	1.82 (1.08, 3.06)	1.82 (1.10, 3.01)	2.12 (1.30, 3.44)	
Yes	1104/170827	1 (reference)	1.18 (0.96, 1.44)	1.26 (1.04, 1.53)	1.50 (1.24, 1.80)	
Hyperlipidemia						0.266
No	344/166814	1 (reference)	1.47 (0.97, 2.23)	1.72 (1.16, 2.56)	1.81 (1.23, 2.65)	
Yes	995/144832	1 (reference)	1.09 (0.88, 1.34)	1.21 (0.99, 1.48)	1.45 (1.19, 1.75)	
Diabetes						0.516
No	1201/293881	1 (reference)	1.20 (0.97, 1.47)	1.34 (1.10, 1.63)	1.55 (1.29, 1.87)	
Yes	138/17765	1 (reference)	1.25 (0.73, 2.14)	1.15 (0.68, 1.96)	1.32 (0.79, 2.21)	

430 Adjusted for age, sex, ethnicity, TDI, education levels body mass index, C-reactive protein, smoking and drinking status, physical activity, sleep
431 and diet patterns, history of hyperlipemia, hypertension, and diabetes mellitus.

432 Abbreviation: TDI, Townsend deprivation index.